Oxford Immunotec Global (NASDAQ:OXFD) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, February 27th. Analysts expect Oxford Immunotec Global to post earnings of ($0.36) per share for the quarter.
Oxford Immunotec Global (OXFD) opened at $11.91 on Tuesday. Oxford Immunotec Global has a 12-month low of $10.00 and a 12-month high of $19.51. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.72 and a quick ratio of 4.30. The company has a market capitalization of $305.55, a P/E ratio of -5.90 and a beta of -0.30.
Several brokerages recently issued reports on OXFD. Piper Jaffray Companies cut their price target on Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, October 31st. BTIG Research set a $21.00 price target on Oxford Immunotec Global and gave the company a “buy” rating in a research note on Monday, December 18th. BidaskClub upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Friday, December 15th. Zacks Investment Research cut Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $20.00 price target on shares of Oxford Immunotec Global in a research note on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $18.75.
An institutional investor recently raised its position in Oxford Immunotec Global stock. Vanguard Group Inc. lifted its stake in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 5.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,043 shares of the company’s stock after buying an additional 3,507 shares during the period. Vanguard Group Inc. owned approximately 0.30% of Oxford Immunotec Global worth $1,161,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 88.00% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://stocknewstimes.com/2018/02/20/oxford-immunotec-global-oxfd-scheduled-to-post-quarterly-earnings-on-tuesday.html.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.